Search - tctmd.com

Displaying 441 - 460 of 560

Sort: Relevancy | Date

Presentation ACC 2017

Results of the CARAT Study: Effect of Serial Infusions of CER-001, a Pre-Beta High-Density Lipoprotein Mimetic on Coronary Atherosclerosis

Presenter: Stephen J Nicholls

March 20, 2017

Presentation ACC 2017

EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Presenter: Jeff Weitz

March 20, 2017

Presentation ACC 2017

EBBINGHAUS: A Cognitive Study of Patients Enrolled in the FOURIER Trial

Presenter: Robert Giugliano

March 19, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery

L.A. McKeown

March 19, 2017

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

Presentation ACC 2017

The RAD-MATRIX Study

Presenter: Alessandro Sciahbasi

March 19, 2017

News Conference News ACC 2017

Radiation Exposure Greater for Radial vs Femoral PCI, RAD-MATRIX Dosimeter Study Confirms

L.A. McKeown

March 19, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

Yael L. Maxwell

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

L.A. McKeown

March 18, 2017

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

Todd Neale

March 18, 2017

Presentation ACC 2017

ORION-1: Primary Efficacy & Safety Outcomes

Presenter: Kausik K. Ray

March 17, 2017

News Conference News ACC 2017

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

People Living in Amazon Rainforest Provide Clues to Coronary Protection

L.A. McKeown

March 17, 2017

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Presentation ACC 2017

Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk

Presenter: Marc Sabatine

March 17, 2017

News Daily News

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Michael O'Riordan

March 16, 2017

Advertisement

Results of the CARAT Study: Effect of Serial Infusions of CER-001, a Pre-Beta High-Density Lipoprotein Mimetic on Coronary Atherosclerosis

EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

EBBINGHAUS: A Cognitive Study of Patients Enrolled in the FOURIER Trial

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

The RAD-MATRIX Study

Radiation Exposure Greater for Radial vs Femoral PCI, RAD-MATRIX Dosimeter Study Confirms

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

ORION-1: Primary Efficacy & Safety Outcomes

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

People Living in Amazon Rainforest Provide Clues to Coronary Protection

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content